NCT06055348View on ClinicalTrials.gov

SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

November 30, 2025

Conditions
Serous Ovarian CancerAdvanced Ovarian Cancer
Interventions
DRUG

SC0191

SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.

DRUG

Gemcitabine

Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.

DRUG

Paclitaxel

Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.

Sponsors
All Listed Sponsors
lead

Biocity Biopharmaceutics Co., Ltd.

INDUSTRY